Medivation, Inc. (MDVN)

81.44
NASDAQ
Prev Close 81.44
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Biotech Is Showing Some Bargains

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.

Medivation upgraded at Citi

Cramer: Where'd All the Growth Go?

Checking the gauges for underperformance, none of them look good.

Pfizer Reportedly Approaches Drugmaker Medivation About a Buyout

Pfizer Reportedly Approaches Drugmaker Medivation About a Buyout

Pfizer (PFE) has reportedly approached San Francisco based cancer drug maker Medivation (MDVN) about a buyout.

Medivation upgraded at Canaccord

M&A Could Ignite Next Leg Up for Biotech

M&A Could Ignite Next Leg Up for Biotech

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.

Just a Routine Market Pullback

This sort of action is needed periodically.

Medivation Surges on Takeover Chatter; Wall Street Scouts for Big Pharma M&A

Medivation is surging as Wall Street scouts the Big Pharma front for discounted M&A opportunities.

Medivation downgraded at Canaccord

Jim Cramer’s Cyber Security Picks Include Palo Alto Networks and Fortinet

Jim Cramer’s Cyber Security Picks Include Palo Alto Networks and Fortinet

With hacking and cyber security making headlines, Jim Cramer recommended a few cyber security stocks for investors, including Palo Alto Networks (PANW), Fortinet (FTNT), FireEye (FEYE), and Cyberark Software (CYBR).

Medivation downgraded at Credit Suisse

3 Biotech Bounce Trades

3 Biotech Bounce Trades

Chart setups in Celgene, Medivation and AMAG Pharmaceuticals.

Stick With the Price Action

It's the only way to deal with this market.

Medivation downgraded at Goldman

Medivation upgraded at Canaccord

An Indication of Weakness

An Indication of Weakness

Consider going short if you aren't already.

Medivation upgraded at Bernstein

Medivation price target, EPS cut at UBS

Medivation downgraded at Needham

Shire Deal Just The Start

Shire Deal Just The Start

Shire's purchase of ViroPharma is a signal of deals and higher prices ahead, says Jason Kolbert, Sr. Research Analyst at the Maxim Group.

Medivation upgraded at UBS

Medivation rated new Buy at Needham

Medivation rated new Neutral at UBS

Medivation numbers raised at Jefferies

The Next Big Thing in Biotech: Earnings

The Next Big Thing in Biotech: Earnings

Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.

Medivation numbers raised at Citigroup

Remember What Really Moves Stocks

Motivated CEOs, innovative products and smart deals count more than macro events.

Medivation numbers raised at Jefferies